Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma
作者： Brian I. Rini , Eric J. Small
关键词:
摘要: Purpose To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial growth factor (VEGF) overexpression and clinical results VEGF blockade in metastatic RCC. Methods A relevant published literature regarding VEGF, von Hippel-Lindau (VHL) gene inactivation RCC was performed. Further, a mechanism, toxicity, development VEGF-targeted therapy undertaken. Results is major proangiogenic protein that exerts biologic effect through interaction with cellular receptors. The majority sporadic clear-cell tumors are characterized by VHL tumor suppressor inactivation. resulting silencing leads overexpression. An antibody (bevacizumab) has demonstrated significant prolongation time disease progression compared placebo patients Small molecules inhibitory effects against receptor have undergone initial ...
sci-hub.se 参考文章(147)
M. Gelati, E. Corsini, S. Frigerio, B. Pollo, G. Broggi, D. Croci, A. Silvani, A. Boiardi, A. Salmaggi, Effects of Thalidomide on Parameters Involved in Angiogenesis: An in vitro Study Journal of Neuro-oncology. ,vol. 64, pp. 193- 201 ,(2003) , 10.1023/A:1025618022921
Alain Renaud, Zarin Kachra, Nathalie Mousseau, Denis Gingras, Richard Beliveau, Edith Beaulieu, Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Research. ,vol. 21, pp. 145- 155 ,(2001)
M. Detmar, A. M. Dvorak, L. F. Brown, H. F. Dvorak, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology. ,vol. 146, pp. 1029- 1039 ,(1995)
Ronald M. Bukowski, Cytokine therapy for metastatic renal cell carcinoma. Seminars in Urologic Oncology. ,vol. 19, pp. 148- 154 ,(2001)
André Luís Moreira, David Raul Friedlander, Bronya Shif, Gilla Kaplan, David Zagzag, Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. Journal of Neuro-oncology. ,vol. 43, pp. 109- 114 ,(1999) , 10.1023/A:1006202700039
Robert J. Motzer, Robert Amato, Mary Todd, Wen‐J Poo Hwu, Roger Cohen, Jose Baselga, Hyman Muss, Michael Cooper, Richard Yu, Michelle S. Ginsberg, Michael Needle, Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Investigational New Drugs. ,vol. 21, pp. 99- 101 ,(2003) , 10.1023/A:1022928612511
J R Sheu, W J Chung, C C Fu, M L Tsai, Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Research. ,vol. 18, pp. 4435- 4441 ,(1998)
David R. Minor, Dana Monroe, Lisa A. Damico, Gloria Meng, Uma Suryadevara, Laurence Elias, A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Investigational New Drugs. ,vol. 20, pp. 389- 393 ,(2002) , 10.1023/A:1020669705369
Xiping Li, Eddie Reed, Yi Zhang, Jie Wang, Yuanlin Liu, Wei Jiang, Zengli Wang, Q Quentin Li, Xuyi Liu, Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells Anticancer Research. ,vol. 23, pp. 2481- 2487 ,(2003)
H. F. Dvorak, J. A. Nagy, D. Feng, L. F. Brown, A. M. Dvorak, Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Current Topics in Microbiology and Immunology. ,vol. 237, pp. 97- 132 ,(1999) , 10.1007/978-3-642-59953-8_6